Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating

2026-01-07 15:00:21 ET

The last time I spoke about Bright Minds Biosciences ( DRUG ) it was with respect to an article entitled " Bright Minds Biosciences: Looking To Change Scope Of Epilepsy Disorder Treatments With BMB-101 ". With respect to this article, I noted that this company was in the process of developing its novel scaffold 5-HT2C Gq-protein biased agonist BMB-101 in difficult-to-treat epilepsy patients. Specifically, the company evaluated this drug in the phase 2 BREAKTHROUGH study targeting patients with drug-resistant Absence Epilepsy and Developmental and Encephalopathic Epilepsies [DEEs]. I had a "Strong Buy" rating on this stock the last time around based on the development of this 5-HT2C agonist and the rest of its pipeline of a similar mechanism of action [MOA] of targeting other neurological disorders. In addition, the stock had gained 153.59% since I last wrote about it back on January 26, 2025. I will be going over the trial data in detail below and why this program is now in even better shape....

Read the full article on Seeking Alpha

For further details see: